GSK to Cut Jobs Amid £1. 9bn Cost Cutting Plan and Bid for Faster Drug Development GlaxoSmithKline's (GSK) announcement of a £1.
9 billion cost cutting plan, coupled with a £400 million investment in UK life sciences, sends mixed signals to investors and analysts.
The company plans to reduce costs by 1,000 job losses and site closures, primarily at its R&D site in Stevenage, which will close by 2029.